Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma to Acquire the Chromatography Business of JSR Life Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News

MilliporeSigma to Acquire the Chromatography Business of JSR Life Sciences

Will expand its downstream processing portfolio with advanced Protein A chromatography capabilities.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has agreed to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions.

The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. The transaction is expected to close by the end of the second quarter of 2026.

“This acquisition will strengthen our position in the bioprocessing market and underscores our commitment to long-term investment in monoclonal antibody production technologies,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “By combining JSR’s Protein A expertise with our portfolio, we can further enable customers to advance the speed, efficiency, and reliability of antibody therapy production.”

Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The company is known for its high-performing Amsphere A3 and Amsphere A+ Protein A resins, which offer superior purification performance and process robustness for a wide range of monoclonal antibodies.

“This acquisition positions our innovative Amsphere Protein A technologies for even greater global impact under Merck’s renowned platform—enabling more customers worldwide to accelerate therapies to market with enhanced speed and confidence,” said Tim Lowery, President of JSR Life Sciences.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics